Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein

Virology

Volumn 395, Issue 1, 2009, Pages 45-55

  Di Bonito, Paola ^a   Grasso, Felicia ^a   Mochi, Stefania ^a   Petrone, Linda ^a   Fanales Belasio, Emanuele ^a   Mei, Arianna ^a   Cesolini, Armando ^a   Laconi, Giuseppe ^a   Conrad, Heinke ^b   Bernhard, Helga ^b   Dembek, Claudia J ^c   Cosma, Antonio ^c   Santini, Stefano M ^a   Lapenta, Caterina ^a   Donati, Simona ^a   Muratori, Claudia ^a   Giorgi, Colomba ^a   Federico, Maurizio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Cross presentation; CTLs; HIV 1 Nef; HPV E7; Protein delivery; Virus like particles

Indexed keywords

FREUND ADJUVANT; NEF PROTEIN; PROTEIN E7; RECOMBINANT PROTEIN; TUMOR ANTIGEN; VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR CELL; VIRUS MUTANT;

ADAPTIVE IMMUNITY; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CROSS-PRIMING; HIV-1; HUMAN PAPILLOMAVIRUS 16; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL ENVELOPE PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

EID: 71749116038     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.09.012     Document Type: Article

References (52)

1. Anderson R.J., and Schneider J. Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 25 Suppl. 2 (2007) B24-B34
2. Bauer S., Heeg K., Wagner H., and Lipford G.B. Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7. Scand. J. Immunol. 42 (1995) 317-323
3. Bellone S., Pecorelli S., Cannon M.J., and Santin A.D. Advances in dendritic cell-based therapeutic vaccines for cervical cancer. Expert Rev. Anticancer Ther. 7 (2007) 1473-1486
4. Bottley G., Watherston O.G., Hiew Y.L., Norrild B., Cook G.P., and Blair G.E. High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene 27 (2008) 1794-1799
5. Bourgault I V., Moyal B.M., Ziol M., Chaboissier A., Barget N., Berville S., Paniel B., Jullian E., Clerici T., Maillere B., and Guillet J.G. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res. 64 (2004) 8761-8766
6. Brinkman J.A., Hughes S.H., Stone P., Caffrey A.S., Muderspach L.I., Roman L.D., Weber J.S., and Kast W.N. Therapeutic vaccination for HPV induced cervical cancer. Dis. Markers 23 (2007) 337-352
7. Bukovsky A.A., Dorfman T., Weimann A., and Gottlinger H.G. Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease. J. Virol. 71 (1997) 1013-1018
8. Buonaguro L., Tornesello M.L., Tagliamonte M., Gallo R.C., Wang L.X., Kamin-Lewis R., Abdelwahab S., Lewis G.K., and Buonaguro F.M. Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J. Virol. 80 (2006) 9134-9143
9. Buseyne F., Le G.S., Boccaccio C., Abastado J.P., Lifson J.D., Arthur L.O., Riviere Y., Heard J.M., and Schwartz O. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat. Med. 7 (2001) 344-349
10. Cosma A., Nagaraj R., Buhler S., Hinkula J., Busch D.H., Sutter G., Goebel F.D., and Erfle V. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22 (2003) 21-29
11. Daftarian P., Mansour M., Benoit A.C., Pohajdak B., Hoskin D.W., Brown R.G., and Kast W.M. Eradication of established HPV 16 expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 24 (2006) 5235-5244
12. D'Aloja P., Santarcangelo A.C., Arold S., Baur A., and Federico M. Genetic and functional analysis of the human immunodeficiency virus (HIV) type 1-inhibiting F12-HIVnef allele. J. Gen. Virol. 82 (2001) 2735-2745
13. Di Bonito P., Grasso F., Mochi S., Accardi L., Dona M.G., Branca M., Costa S., Mariani L., Agarossi A., Ciotti M., Syrjanen K., and Giorgi C. Serum antibody response to human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. Infect. Agent. Cancer 1 (2006) 6
14. Federico M., Percario Z., Olivetta E., Fiorucci G., Muratori C., Micheli A., Romeo G., and Affabris E. HIV-1 Nef activates STAT1 in human monocytes/macrophages through the release of soluble factors. Blood 98 (2001) 2752-2761
15. Fehrmann F., and Laimins L.A. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 22 (2003) 5201-5207
16. Fostel L.V., Dluzniewska J., Shimizu Y., Burbach B.J., and Peterson E.J. ADAP is dispensable for NK cell development and function. Int. Immunol. 18 (2006) 1305-1314
17. Geretti A.M., Dings M.E., van Els C.A., van Baalen C.A., Wijnholds F.J., Borleffs J.C., and Osterhaus A.D. Human immunodeficiency virus type 1 (HIV-1)- and Epstein-Barr virus-specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1-infected persons. J. Infect. Dis. 174 (1996) 34-45
18. Gorer P.A. Studies in antibody response of mice to tumour inoculation. Br. J. Cancer 4 (1950) 372-379
19. Green L.A., Liu Y., and He J.J. Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy. J. Biol. Chem. 284 (2009) 13363-13372
20. Grgacic E.V., and Anderson D.A. Virus-like particles: passport to immune recognition. Methods 40 (2006) 60-65
21. He Y., Munn D., and Falo Jr. L.D. Recombinant lentivector as a genetic immunization vehicle for antitumor immunity. Expert. Rev. Vaccines. 6 (2007) 913-924
22. Hung C.F., Monie A., Alvarez R.D., and Wu T.C. DNA vaccines for cervical cancer: from bench to bedside. Exp. Mol. Med. 39 (2007) 679-689
23. Kattenbeck B., von P.A., Rohrhofer A., Wolf H., and Modrow S. Inhibition of human immunodeficiency virus type 1 particle formation by alterations of defined amino acids within the C terminus of the capsid protein. J. Gen. Virol. 78 (1997) 2489-2496
24. Klasse P.J., and Sattentau Q.J. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 83 (2002) 2091-2108
25. Kutscher S., Dembek C.J., Allgayer S., Heltai S., Stadlbauer B., Biswas P., Nozza S., Tambussi G., Bogner J.R., Stellbrink H.J., Goebel F.D., Lusso P., Tinelli M., Poli G., Erfle V., Pohla H., Malnati M., and Cosma A. The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT. AIDS Res. Ther. 5 (2008) 22
26. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., and Wu T.C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56 (1996) 21-26
27. Liniger M., Zuniga A., and Naim H.Y. Use of viral vectors for the development of vaccines. Expert Rev. Vaccines 6 (2007) 255-266
28. Liu M.A., and Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv. Genet. 55 (2005) 25-40
29. Luo L., Li Y., Ha S.D., and Kang C.Y. Hydrophilicity dependent budding and secretion of chimeric HIV Gag-V3 virus-like particles. Virus Genes 35 (2007) 187-193
30. Marsac D., Loirat D., Petit C., Schwartz O., and Michel M.L. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles. J. Virol. 76 (2002) 7544-7553
31. Moris A., Nobile C., Buseyne F., Porrot F., Abastado J.P., and Schwartz O. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood 103 (2004) 2648-2654
32. Muller B., Daecke J., Fackler O.T., Dittmar M.T., Zentgraf H., and Krausslich H.G. Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J. Virol. 78 (2004) 10803-10813
33. Munger K., Baldwin A., Edwards K.M., Hayakawa H., Nguyen C.L., Owens M., Grace M., and Huh K. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78 (2004) 11451-11460
34. Munz C., Bickham K.L., Subklewe M., Tsang M.L., Chahroudi A., Kurilla M.G., Zhang D., O'Donnell M., and Steinman R.M. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med. 191 (2000) 1649-1660
35. Muratori C., D'Aloja P., Superti F., Tinari A., Sol-Foulon N., Sparacio S., Bosch V., Schwartz O., and Federico M. Generation and characterization of a stable cell population releasing fluorescent HIV-1-based virus like particles in an inducible way. BMC Biotechnol. 6 (2006) 52
36. Paliard X., Liu Y., Wagner R., Wolf H., Baenziger J., and Walker C.M. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retroviruses 16 (2000) 273-282
37. Pandori M.W., Fitch N.J., Craig H.M., Richman D.D., Spina C.A., and Guatelli J.C. Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J. Virol. 70 (1996) 4283-4290
38. Peretti S., Schiavoni I., Pugliese K., and Federico M. Cell death induced by the herpes simplex virus-1 thymidine kinase delivered by human immunodeficiency virus-1-based virus-like particles. Mol. Ther. 12 (2005) 1185-1196
39. Peretti S., Schiavoni I., Pugliese K., and Federico M. Selective elimination of HIV-1-infected cells by Env-directed, HIV-1-based virus-like particles. Virology 345 (2006) 115-126
40. Reading S.A., and Dimmock N.J. Neutralization of animal virus infectivity by antibody. Arch. Virol. 152 (2007) 1047-1059
41. Sallusto F., and Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179 (1994) 1109-1118
42. Schafer K., Muller M., Faath S., Henn A., Osen W., Zentgraf H., Benner A., Gissmann L., and Jochmus I. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int. J. Cancer 81 (1999) 881-888
43. Schwartz O., Marechal V., Le G.S., Lemonnier F., and Heard J.M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat. Med. 2 (1996) 338-342
44. Selvey L.A., Dunn L.A., Tindle R.W., Park D.S., and Frazer I.H. Human papillomavirus (HPV) type 18 E7 protein is a short-lived steroid-inducible phosphoprotein in HPV-transformed cell lines. J. Gen. Virol. 75 (1994) 1647-1653
45. Smahel M., Sima P., Ludvikova V., and Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281 (2001) 231-238
46. Sparacio S., Pfeiffer T., Schaal H., and Bosch V. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. Mol. Ther. 3 (2001) 602-612
47. Wagner R., Deml L., Fliessbach H., Wanner G., and Wolf H. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology 200 (1994) 162-175
48. Wang Z., La R.C., Lacey S.F., Maas R., Mekhoubad S., Britt W.J., and Diamond D.J. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J. Clin. Virol. 35 (2006) 324-331
49. Wonderlich E.R., Williams M., and Collins K.L. The tyrosine binding pocket in the adaptor protein 1 (AP-1) mu1 subunit is necessary for Nef to recruit AP-1 to the major histocompatibility complex class I cytoplasmic tail. J. Biol. Chem. 283 (2008) 3011-3022
50. Yang T.C., Millar J.B., Grinshtein N., Bassett J., Finn J., and Bramson J.L. T-cell immunity generated by recombinant adenovirus vaccines. Expert. Rev. Vaccines 6 (2007) 347-356
51. Young K.R., and Ross T.M. Elicitation of immunity to HIV type 1 Gag is determined by Gag structure. AIDS Res. Hum. Retroviruses 22 (2006) 99-108
52. zum Buschenfelde C.M., Metzger J., Hermann C., Nicklisch N., Peschel C., and Bernhard H. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J. Immunol. 167 (2001) 1712-1719